Phillips Wealth Planners LLC Buys Shares of 1,364 IQVIA Holdings Inc. $IQV

Key Points

• Phillips Wealth Planners LLC acquired a new position in IQVIA Holdings Inc., purchasing 1,364 shares valued at approximately $224,000 during the second quarter.
• Analysts have a consensus rating of "Moderate Buy" for IQVIA, with price targets recently raised by several firms, including a new target of $235.00 from Truist Financial.
• The company reported a quarterly EPS of $2.81, surpassing estimates, and set its FY 2025 guidance at 11.750-12.050 EPS, indicating continued growth potential.

Phillips Wealth Planners LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,364 shares of the medical research company's stock, valued at approximately $224,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. American National Bank & Trust purchased a new stake in shares of IQVIA during the 1st quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its stake in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the first quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of several research analyst reports. Truist Financial increased their price target on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Robert W. Baird lifted their price target on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Evercore ISI lifted their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Price Performance

Shares of IQVIA stock traded up $0.20 during trading on Tuesday, hitting $188.03. 200,161 shares of the company's stock traded hands, compared to its average volume of 1,869,843. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm's fifty day moving average price is $185.35 and its 200 day moving average price is $167.16. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $241.88. The company has a market cap of $31.96 billion, a PE ratio of 27.21, a PEG ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.